Se-Hoon Kim et al., 2025: Canine melanoma study in which abemaciclib causes G1 arrest and lysosomal dysfunction and combines synergistically with fenbendazole within defined dose ranges; in a xenograft, abemaciclib alone or with fenbendazole suppressed tumour growth.
Co-treatment with fenbendazole enhanced cytotoxicity and showed synergistic effects within specific dose ranges.
Se-Hoon Kim et al., 2025: Canine melanoma study in which abemaciclib causes G1 arrest and lysosomal dysfunction and combines synergistically with fenbendazole within defined dose ranges; in a xenograft, abemaciclib alone or with fenbendazole suppressed tumour growth. Study type: five canine melanoma cell lines plus a xenograft model. N: not stated in the abstract. Country: Korea (Konkuk University; Seoul National University). Dose: synergism at fenbendazole below 2 micromolar in CMeC1 and below 1 micromolar in KMeC (full text). Funder: not stated in the record. Declared conflicts: 'K-HS was employed by ViroCure Inc.' Comparator: each drug alone, scored with the Highest Single Agent method.
